Literature DB >> 19957231

Multiple endocrine neoplasia type 1: clinical manifestations and management.

Anathea C Powell1, Steven K Libutti.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 19957231     DOI: 10.1007/978-1-4419-0857-5_16

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


× No keyword cloud information.
  6 in total

1.  Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

Authors:  Thomas J Quinn; Ziqiang Yuan; Asha Adem; Rula Geha; Chakravarthy Vrikshajanani; Wade Koba; Eugene Fine; David T Hughes; Herbert A Schmid; Steven K Libutti
Journal:  Surgery       Date:  2012-10-24       Impact factor: 3.982

Review 2.  Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas.

Authors:  Ian W Folkert; Paul Hernandez; Robert E Roses
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

3.  Gastroenteropancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Francesco Tonelli; Francesco Giudici; Francesca Giusti; Maria Luisa Brandi
Journal:  Cancers (Basel)       Date:  2012-05-07       Impact factor: 6.639

Review 4.  Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.

Authors:  Mark Kidd; Irvin M Modlin; Lisa Bodei; Ignat Drozdov
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-01-12

5.  Current concepts on gastric carcinoid tumors.

Authors:  George C Nikou; Theodoros P Angelopoulos
Journal:  Gastroenterol Res Pract       Date:  2012-12-17       Impact factor: 2.260

6.  Multiple endocrine neoplasia type 1 with a frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas: case report.

Authors:  Yoshiro Fushimi; Shinji Kamei; Fuminori Tatsumi; Junpei Sanada; Masashi Shimoda; Tomohiko Kimura; Atsushi Obata; Shuhei Nakanishi; Kohei Kaku; Tomoatsu Mune; Hideaki Kaneto
Journal:  BMC Endocr Disord       Date:  2021-08-12       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.